title: [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
abstract: The chimeric antibody directed against tumor necrosis factor- alpha (TNF alpha) Infliximab (Remicade) is effective in the therapy of Crohn's disease. This is rather surprising since it was unlikely that single factor should be effective, considering the complexity and redundance of the mucosal cytokine system. Because of safety reasons and high cost the indication should be restrictive.
authors.affiliation: Medizinische Klinik I, Gastroenterologie, Medizinische Universität Lübeck, Germany. eduard.stange@rbk.de
authors.forename: E F
authors.initials: EF
authors.lastname: Stange
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016207:Cytokines / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D000069285:Infliximab; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
vernacular_title: Chronisch-entzündliche Darmerkrankungen - Neue Therapien: Tumornekrosefaktor-Antikörper und Cytokine.